Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.

CONCLUSIONS: Infliximab appears to be a beneficial treatment for chronic cutaneous sarcoidosis. The SASI scoring system demonstrated significant improvement versus placebo in lesion desquamation and induration. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 289-295). PMID: 26847095 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/26847095?dopt=Abstract

Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - February 9, 2016 Category: Respiratory Medicine Tags: Sarcoidosis Vasc Diffuse Lung Dis Source Type: research